Regeneron’s Ultra-Orphan Arcalyst Hits The Market With A Rare Price
This article was originally published in The Pink Sheet Daily
Executive Summary
$250,000 per year wholesale acquisition cost to treat rare genetic disorder, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.
Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned
Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.
Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned
Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.